Axatilimab

Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases[1][2].

Product Specifications

CAS Number

[2155851-88-8]

Product Name Alternative

SNDX-6352

UNSPSC

12352203

Target

C-Fms

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/axatilimab.html

Purity

99.59

Solubility

H2O

Smiles

[Axatilimab]

Molecular Weight

(147.18 kDa)

References & Citations

[1]Arora M, et al. Phase 1 study of axatilimab (SNDX-6352), a CSF-1R humanized antibody, for chronic graft-versus-host disease after 2 or more lines of systemic treatment. Blood, 2020, 136: 1-2.|[2]Tiessen R, et al. First in human, single ascending dose study in healthy volunteers of SNDX-6352, a humanized IgG4 monoclonal antibody targeting colony stimulating factor-1 receptor (CSF-1R) . J Immunother Cancer, 2016, 5: P505.